in Sierra Leone, will not receive the experimental drug ZMapp because
world supplies are exhausted, Madrid health authorities said on
Monday.
ZMapp was used to treat several Ebola patients who recovered. Its use
is part of a push by drug manufacturers to devise a cure or a vaccine
for the disease, which has killed about 48 percent of those infected
in the current epidemic.
Manuel Garcia Viejo, 69, was taken to Madrid's Carlos III hospital at
about 0200 GMT after he was repatriated.
Canadian drugmaker, Tekmira Pharmaceuticals Corp, said on Monday that
U.S. and Canadian regulators have authorized the use of its Ebola
treatment in patients who have confirmed or suspected infections.
The Vancouver-based company said its treatment, TKM-Ebola, has been
administered to patients on an emergency basis and the repeat
infusions have been well-tolerated.
Meanwhile, independent health advisers to the WHO have assessed that
there should be no general ban on travel or trade with countries where
the virus has struck, but some airlines have maintained suspensions on
flights to affected areas.
The WHO and other agencies say this hampers aid efforts and the
ability of experts to reach victims. "The (WHO Emergency) Committee
strongly reiterated that there should be no general ban on
international travel or trade," WHO said.
No comments:
Post a Comment